Lack of effect of central nervous system-active doses of nabilone on capsaicin-induced pain and hyperalgesia

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 4, 2012, Pages 336-342

  Kalliomäki, Jarkko ^a   Philipp, Andrew ^b   Baxendale, Jane ^b   Annas, Peter ^a   Karlsten, Rolf ^a   Segerdahl, Märta ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ICON Development Solutions   (United States)

Author keywords

Cannabinoid; Capsaicin; Clinical trials; Nabilone; Pain

Indexed keywords

BIOLOGICAL MARKER; CANNABINOID; CAPSAICIN; METHANOL; NABILONE; PLACEBO;

ADULT; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOREARM; HUMAN; HYPERALGESIA; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PAIN; PAIN THRESHOLD; PERCEPTION DISORDER; RANDOMIZED CONTROLLED TRIAL; SEDATION; STIMULUS RESPONSE; TACTILE STIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNCONSCIOUSNESS; VISUAL ANALOG SCALE;

ADULT; CAPSAICIN; CENTRAL NERVOUS SYSTEM; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; TETRAHYDROCANNABINOL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858992804     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2012.05674.x     Document Type: Article

References (40)

1. Campbell FA, Tramer MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 1-6.
2. Martin-Sanchez E, Furukawa TA, Taylor J, Martin JLR. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009; 10: 1353-68.
3. Karst M, Salim K, Burstein S, Konrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. JAMA 2003; 290: 1757-62.
4. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: A randomized, double-blind, placebo-controlled clinical trial. Pain 2007; 133: 210-20.
5. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-19.
6. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329: 253-60.
7. Zajicek J, Fox P, Sanders H et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-26.
8. Abrams DI, Jay CA, Shade SB et al. Cannabis in painful HIV-associated sensory neuropathy. Neurology 2007; 68: 515-21.
9. Ellis RJ, Toperoff W, Vaida F et al. Smoked medicinal cannabis for neuropathic pain in HIV. A randomized, crossover clinical trial. Neuropsychopharmacology 2009; 34: 672-80.
10. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can. J. Anaesth. 2006; 53: 769-75.
11. Holdcroft A, Maze M, Doré C, Tebbs S, Thompson S. A multicenter study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006; 104: 1040-6.
12. Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J. Clin. Pharmacol. 1981; 21(Suppl. 8-9): S320-6.
13. Kraft B, Frickey NA, Kaufmann RA et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008; 109: 101-10.
14. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003; 105: 79-88.
15. Noyes R Jr, Brunk SF, Avery DAH, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin. Pharmacol. Ther. 1975; 18: 84-9.
16. Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003; 102: 283-8.
17. Wallace M, Schulteis G, Atkinson JH et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007; 107: 785-96.
18. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Clin. Pharmacol. 2009; 156: 397-411.
19. Piomelli D. The endocannabinoid system; A drug discovery perspective. Curr. Opin. Invest. Drugs 2005; 6: 672-9.
20. Holdcroft A, Hargreaves KM, Rice ASC, Pertwee RG. Cannabinoids and pain modulation in animals and humans. In: Devor M, Rowbotham MC, Wiesenfeld-Hallin Z (eds). Progress in Pain Research and Management. IASP Press, Seattle. 2000; 915-26.
21. Rice ASC, Farquhar-Smith WP, Bridges D, Brooks JW. Cannabinoids and pain. In: Dostrovsky JO, Carr DB, Koltzenburg M (eds). Progress in Pain Research and Management. IASP Press, Seattle. 2003; 437-68.
22. 2) on sensory nerve fibers and adnexal structures in human skin. J. Derm. Sci. 2005; 38: 177-88.
23. Agarwal N, Pacher P, Tegeder I et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 2007; 10: 870-9.
24. Clapper JR, Moreno-Sanz G, Russo R et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 2010; 13: 1265-70.
25. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl Acad. Sci. USA 2005; 102: 3093-8.
26. 2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol. Neurobiol. 2007; 36: 26-35.
27. Yu XH, Cao CQ, Martino G et al. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain. Pain 2010; 151: 337-44.
28. Simone DA, Baumann TK, LaMotte RH. Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. Pain 1989; 38: 99-107.
29. Harding LM, Murphy A, Kinnman E, Baranowski AP. Characterization of secondary hyperalgesia produced by topical capsaicin jelly: A new experimental tool for pain research. Eur. J. Pain 2001; 5: 363-71.
30. Pertwee RG. Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin. Invest. Drugs 2000; 9: 1553-71.
31. Folstein MF, Luria R. Reliability, validity, and clinical application of the visual analogue mood scale. Psychol. Med. 1973; 3: 479-86.
32. Wesnes KA, Annas P, Edgar CJ et al. Nabilone produces marked impairment to cognitive function and changes in subjective state in healthy volunteers. J. Psychopharmacol. 2010; 24: 1659-69.
33. Lemberger L, Rowe H. Clinical pharmacology of nabilone, a cannabinol derivative. Clin. Pharmacol. Ther. 1975; 18: 720-6.
34. Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med. 2006; 7: 25-9.
35. Glass RM, Uhlenhuth EH, Hartel FW, Schuster CR, Fischman MW. Single-dose study of nabilone in anxious volunteers. J. Clin. Pharmacol. 1981; 21: S383-96.
36. Rubin A, Lemberger L, Warrick P et al. Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin. Pharmacol. Ther. 1977; 22: 85-91.
37. Liu M, Max MB, Robinowitz E et al. The human capsaicin model of allodynia and hyperalgesia: Sources of variability and methods for reduction. J. Pain Symptom Manage. 1998; 16: 10-20.
38. Zuurmann L, Ippel AE, Moin E, van Gerven JMA. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br. J. Clin. Pharmacol. 2008; 67: 5-21.
39. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Randomised, crossover, double blind study. BMJ 2008; 336: 199-201.
40. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J. Pain 2008; 9: 164-73.